타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tocilizumab |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Chronic Lymphocytic Leukemia |
Overview Indication | Multiple Myeloma (MM); Multiple Myeloma Refractory |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Positioning Key differentiator | novel directions and drug candidates for the treatment of CAR-T cell therapy-induced myocardial toxicity |
Positioning Known limitation | resistance to first- and second-line therapies |
MoA Mechanism | checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an immune-related adverse event (irAE) follo |
MoA Biomarker | biomarker for predicting treatment response in RA patients |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tocilizumab |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Chronic Lymphocytic Leukemia |
Overview Indication | Multiple Myeloma (MM); Multiple Myeloma Refractory |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Positioning Key differentiator | novel directions and drug candidates for the treatment of CAR-T cell therapy-induced myocardial toxicity |
Positioning Known limitation | resistance to first- and second-line therapies |
MoA Mechanism | checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an immune-related adverse event (irAE) follo |
MoA Biomarker | biomarker for predicting treatment response in RA patients |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교